0001209191-17-054197.txt : 20170927
0001209191-17-054197.hdr.sgml : 20170927
20170927214131
ACCESSION NUMBER: 0001209191-17-054197
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170925
FILED AS OF DATE: 20170927
DATE AS OF CHANGE: 20170927
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wiezorek Jeffrey
CENTRAL INDEX KEY: 0001610823
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36508
FILM NUMBER: 171105433
MAIL ADDRESS:
STREET 1: C/O KITE PHARMA, INC.
STREET 2: 2225 COLORADO AVENUE
CITY: SANTA MONICA
STATE: CA
ZIP: 90404
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kite Pharma, Inc.
CENTRAL INDEX KEY: 0001510580
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
BUSINESS ADDRESS:
STREET 1: 2225 COLORADO AVENUE
CITY: SANTA MONICA
STATE: CA
ZIP: 90404
BUSINESS PHONE: (310) 824-9999
MAIL ADDRESS:
STREET 1: 2225 COLORADO AVENUE
CITY: SANTA MONICA
STATE: CA
ZIP: 90404
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-09-25
0
0001510580
Kite Pharma, Inc.
KITE
0001610823
Wiezorek Jeffrey
C/O KITE PHARMA, INC.
2225 COLORADO AVENUE
SANTA MONICA
CA
90404
0
1
0
0
SVP Clinical Development
Common Stock
2017-09-25
4
A
0
10000
0.00
A
31107
D
Common Stock
2017-09-25
4
S
0
5283
179.6639
D
25824
D
Includes 36 shares acquired under the 2014 Employee Stock Purchase Plan on August 18, 2017.
The shares were sold to cover the tax obligation that occurred upon the vesting of an RSU.
/s/ David M. Tanen, Attorney-in-Fact
2017-09-27